Evidence map›Paper›PMID 35301331›Full record

ReviewNPJ vaccines2022

Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development.

Megan A Files, Clairissa A Hansen, Vanessa C Herrera, Craig Schindewolf, Alan D T Barrett, David W C Beasley, Nigel Bourne, Gregg N Milligan

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 4 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 4 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. A bibliometric analysis of Oropouche virus.Frontiers in microbiology · 2024
    Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Five Hot Topics in Tropical Medicine: 2025.Infectious disease reports · 2026
    Review
  12. Article
  13. Review
  14. The global outbreak of Oropouche virus: surveillance of global trends.Tropical diseases, travel medicine and vaccines · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Megan A Files *Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0002-5064-0490
Clairissa A Hansen *Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0002-4841-2456
Vanessa C Herrera *Department of Preventive Medicine and Population Health, University of Texas Medical Branch, Galveston, TX, USA.
Craig Schindewolf *Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Alan D T BarrettDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. abarrett@utmb.edu.ORCID http://orcid.org/0000-0003-3740-7448
David W C BeasleyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0002-3252-690X
Nigel BourneSealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
Gregg N MilliganSealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
The University of Texas Medical Branch at Galveston · USWashington State Department of Health · USWorld Health Organization - Pakistan · PK

Funding

EMERGING AND TROPICAL INFECTIOUS DISEASEST32AI007526 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SOONG, LYNN · 1997 to 2025
$3.1M
NIAID NIH HHS T32 AI007526
6 · The paper itself

Abstract

Oropouche virus (OROV) is an arthropod-borne orthobunyavirus found in South America and causes Oropouche fever, a febrile infection similar to dengue. It is the second most prevalent arthropod-borne viral disease in South America after dengue. Over 500,000 cases have been diagnosed since the virus was first discovered in 1955; however, this is likely a significant underestimate given the limited availability of diagnostics. No fatalities have been reported to date, however, up to 60% of cases have a recurrent phase of disease within one month of recovery from the primary disease course. The main arthropod vector is the biting midge Culicoides paraensis, which has a geographic range as far north as the United States and demonstrates the potential for OROV to geographically expand. The transmission cycle is incompletely understood and vertebrate hosts include both non-human primates and birds further supporting the potential ability of the virus to spread. A number of candidate antivirals have been evaluated against OROV in vitro but none showed antiviral activity. Surprisingly, there is only one report in the literature on candidate vaccines. We suggest that OROV is an undervalued pathogen much like chikungunya, Schmallenberg, and Zika viruses were before they emerged. Overall, OROV is an important emerging disease that has been under-investigated and has the potential to cause large epidemics in the future. Further research, in particular candidate vaccines, is needed for this important pathogen.

Identifiers

PMID35301331
PMCPMC8931169
OpenAlexW4220822593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.